Skip to main content
profile image
Selected Works of Suresh G. Nair, MD
Article
Immunoscore Is Prognostic in Low-Risk and High-Risk Stage III Colon Carcinomas Treated With Adjuvant Infusional Fluorouracil, Leucovorin, and Oxaliplatin in a Phase III Trial.
JCO Precis Oncol
  • Frank A Sinicrope, Mayo Clinic
  • Qian Shi, Alliance Statistics and Data Center
  • Aurelie Catteau, Veracyte Inc
  • Graham M Poage, Veracyte Inc
  • Tyler J Zemla, Alliance Statistics and Data Center
  • Bernhard Mlecnik, INSERM, UMRS 1138, Laboratory of Integrative Cancer Immunology
  • Al B Benson, Northwestern University
  • Sharlene Gill, British Columbia Cancer Agency-Vancouver Cancer Center
  • Richard M Goldberg, West Virginia Cancer Institute
  • Morton S Kahlenberg, Surgical Oncology Associates of South Texas
  • Suresh G. Nair, MD, Lehigh Valley Health Network
  • Anthony F Shields, Karmanos Cancer Institute
  • Thomas C Smyrk, Mayo Clinic
  • Jerome Galon, INSERM, UMRS 1138, Laboratory of Integrative Cancer Immunology
  • Steven R Alberts, Mayo Clinic
Link Find in your library
Publication/Presentation Date
8-1-2022
Abstract

PURPOSE: The recommended duration of adjuvant fluoropyrimidine and oxaliplatin chemotherapy for patients with stage III colon cancer is based on tumor classification into clinically low-risk (T

MATERIALS AND METHODS: Patients with stage III colon carcinomas (N = 600) were randomly selected from the infusional fluorouracil, leucovorin, and oxaliplatin arm of adjuvant trial NCCTG N0147 (Alliance for Clinical Trials in Oncology). Tumors were evaluated for Immunoscore that quantifies CD3

RESULTS: Of 559 cancers with Immunoscore data, 299 (53.5%) were classified as clinically low-risk (T

CONCLUSION: Immunoscore can refine patient prognosis beyond clinical risk group classification, suggesting its potential utility for adjuvant decision making.

Disciplines
PubMedID
35952316
Document Type
Article
Citation Information

Sinicrope FA, Shi Q, Catteau A, Poage GM, Zemla TJ, Mlecnik B, Benson AB, Gill S, Goldberg RM, Kahlenberg MS, Nair SG, Shields AF, Smyrk TC, Galon J, Alberts SR. Immunoscore Is Prognostic in Low-Risk and High-Risk Stage III Colon Carcinomas Treated With Adjuvant Infusional Fluorouracil, Leucovorin, and Oxaliplatin in a Phase III Trial. JCO Precis Oncol. 2022 Aug;6:e2200010. doi: 10.1200/PO.22.00010.